Document Detail


Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy.
MedLine Citation:
PMID:  2540109     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Severe progressive immunodeficiency syndrome can be induced experimentally with a molecularly cloned isolate of feline leukemia virus (FeLV-FAIDS). The resultant disease syndrome is characterized by persistent viremia, lymphopenia, progressive weight loss, persistent diarrhea, enteropathy, and opportunistic infections. The onset of clinical immunodeficiency disease is prefigured by the replication of the FeLV-FAIDS variant virus in bone marrow and other tissues. The FeLV-FAIDS system can be used to evaluate antiviral agents which act on steps in the replication cycle which are conserved among retroviruses (e.g. reverse transcriptase, protease, assembly). The persistence and magnitude of viremia serves as a useful parameter in antiviral studies because it can be easily measured, presages the eventual development of immunodeficiency, and provides a convenient indicator of therapeutic efficacy either in preventing de novo FeLV infection or in reversing or ameliorating established infection. We describe here the evaluation of 2',3'-dideoxycytidine (ddC) against FeLV-FAIDS infection - both in vitro in cell culture assay systems and in vivo in cats administered ddC either via intravenous bolus dosage or via controlled release subcutaneous implants. We found that, although controlled release delivery of ddC inhibited de novo FeLV-FAIDS replication and delayed onset of viremia when therapy was discontinued (after 3 weeks), an equivalent incidence and level of viremia were established rapidly in both ddC-treated and control cats. The FeLV model, therefore, can be used to assess rapidly experimental single agent or combined antiviral therapies for persistent retrovirus infection and disease.
Authors:
E A Hoover; N S Zeidner; N A Perigo; S L Quackenbush; J D Strobel; D L Hill; J I Mullins
Related Documents :
19178669 - Description of clinical and pathological findings, treatment and outcome of feline larg...
9491919 - Partial protection by vaccination with recombinant feline immunodeficiency virus surfac...
2240369 - Human t cell lymphotropic virus infection in guaymi indians from panama.
6306469 - The hardy-zuckerman 2-fesv, a new feline retrovirus with oncogene homology to abelson-m...
7662579 - Htlv-i-associated lymphoma presenting as mycosis fungoides in an htlv-i non-endemic are...
20136999 - Late onset and rapid progression of cerebellar abiotrophy in a domestic shorthair cat.
24836299 - Viral nanoparticles, noble metal decorated viruses and their nanoconjugates.
2480079 - Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human a...
20161679 - Dengue virus markers of virulence and pathogenicity.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Intervirology     Volume:  30 Suppl 1     ISSN:  0300-5526     ISO Abbreviation:  Intervirology     Publication Date:  1989  
Date Detail:
Created Date:  1989-05-26     Completed Date:  1989-05-26     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0364265     Medline TA:  Intervirology     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  12-25     Citation Subset:  IM; X    
Affiliation:
Department of Pathology, Colorado State University, Fort Collins 80523.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acquired Immunodeficiency Syndrome / drug therapy*
Animals
Cats*
Cell Line
Cytopathogenic Effect, Viral
Delayed-Action Preparations
Dideoxynucleosides / administration & dosage,  therapeutic use*
Disease Models, Animal*
Drug Evaluation, Preclinical
Drug Implants
Drug Therapy, Combination
Immunologic Deficiency Syndromes / drug therapy*
Injections, Intravenous
Injections, Subcutaneous
Leukemia Virus, Feline / drug effects
Leukemia, Experimental / drug therapy
Retroviridae Infections / drug therapy
Specific Pathogen-Free Organisms
Tetrahydrouridine / therapeutic use
Viremia / drug therapy
Zalcitabine
Grant Support
ID/Acronym/Agency:
CA43216/CA/NCI NIH HHS; N01 AI62524/AI/NIAID NIH HHS; N01 AI72663/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 0/Dideoxynucleosides; 0/Drug Implants; 18771-50-1/Tetrahydrouridine; 7481-89-2/Zalcitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Turcot syndrome: report of a case and review of the literature.
Next Document:  Murine models for antiretroviral therapy.